7 November 2024 in RMD Open
Objectives Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by the synovitis and bone erosion. The combination therapy of glucocorticoids (GCs) and methotrexate (MTX) is recommended in early RA management, although the precise underlying mechanism of action remains unclear. This study is aimed to clarify the mechanism of MTX in combined with GC in treating RA. Methods GC-induced osteoporosis (GIOP) mouse model was used to investigate the bone-protective role of MTX. Lipopolysaccharide-induced arthritis mouse model was used to evaluate the anti-inflammatory effects of GCs and MTX. Functional role of MTX on osteoclastogenesis was assessed by trap staining and micro-computer tomography. Western blot, RT-qPCR and coimmunoprecipitation were used to explore the underlying mechanisms. Results We demonstrate that GCs, but not MTX, rapidly inhibited synovitis in arthritis model. MTX treatment was observed to inhibit osteoclastogenesis induced by GC in vitro and mitigate bone loss attributed by GIOP. GCs were found to augment the interaction between the membrane GC receptor (mGR) and signal transducer and activator of transcription 1 (STAT1), leading to the suppression of IFN-γR/STAT1 signalling pathways. Interestingly, MTX was found to inhibit osteoclastogenesis induced by GCs through the enhancement of the A2AR and IFN-γR interaction, thereby activating the IFN-γR/STAT1 signalling cascade. Consequently, this process results in a reduction in the mGR and STAT1 interaction. Conclusions Our study provides compelling evidence that MTX can make GCs effectively to suppress synovitis and reduce bone loss induced by GCs. This sheds light on the potential mechanistic insights underlying the efficacy of GCs in conjunction with MTX for treating RA.
1 April 2024 in Translational Cancer Research
Background: Hepatocellular carcinoma (HCC) is the major histological type of primary liver cancer with a relatively poor prognosis, because most HCC cases are usually diagnosed at an advanced stage. Thus, it is essential to explore novel candidate biomarkers for early diagnosis and prognosis predication of HCC. Methods: HCC transcription sequencing data were downloaded and analyzed. POLA2 expression pattern was characterized in tumor development process. POLA2 expression was evaluated by western blotting. Kaplan-Meier plot was utilized to evaluate POLA2’s ability for prognosis predication. Correlation analysis and enrichment analysis were performed to explore the functional role of POLA2 in HCC development. Knockdown of E2F1 or E2F4 was used to evaluate their ability in regulating POLA2 expression. CYBERSORT (https://cibersortx.stanford.edu/) was used to estimate the infiltration levels of immune cells. Results: POLA2 was overexpressed in HCC. Moreover, western blotting results showed that POLA2 was upregulated by transcription factors E2F1 rather than E2F4 in HCC. POLA2 facilitated cell cycle progression, DNA replication and DNA repair. High POLA2 expression was correlated with poor overall survival in HCC patients. POLA2 induced macrophage infiltration in the tumor microenvironment by upregulating the expression CSF1 and VEGFA expression. Conclusions: POLA2 is a novel diagnostic and prognostic biomarker of HCC with potential clinical value.
15 December 2025 in European Journal of Rheumatology
Methotrexate (MTX) remains a cornerstone in the management of rheumatoid arthritis (RA). Extensive basic pharmacological research has consistently demonstrated the e cacy of MTX in treating RA, while there is still insu cient understanding about the potential mechanisms. In this review, current knowledge on the mechanisms by which MTX acts in bone erosion and synovitis is summarized, and MTX-based combination therapies are discussed. Additionally, the bone-protective and anti-in%am matory roles of adenosine receptors are described, and biomarkers associated with MTX responders in RA are explored. This review sheds new light on future research directions for RA, as well as o ers evidence-based recommendations to enhance the clinical utilization of MTX in RA treatment. Cite this article as: Teng Y, Jiang L, Yin H, Deng G. The role and mechanistic e ects of methotrexate in the treatment of rheumatoid arthritis. Eur J Rheumatol. 2025:12(4), -0086, 10.5152/ eurjrheum.2025.24086.